.jpg?w=340&itok=pe6jmFAz "IPT discussed in technical publications."){kind=icon}
Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
-
Life Sciences special feature
ICON recently contributed to the Irish Times Life Sciences special feature with expert commentary from Dr. Nuala Murphy, President of Clinical Research Services, a case study with CFO Brendan Brennan, and a report on career opportunities for clinical researchers with a job profile of Rory Considine, Clinical Operations Manager.
-
Rediscovering HIV: A new decade of research and innovation on the horizon
Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
-
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
Moving from on-site" to agile: The changing dynamic in study management"
Pharmafocus (pages 16-17) features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
-
ICON talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter (pages 14 & 15) features a Q&A with EB McLindon, Senior VP, Site, Patient and Decentralised Solutions, on the inclusivity of decentralised clinical trials.
-
Clinical trials shift to hybrid approaches in the age of COVID-19 and beyond
An article examining the state of clinical trials for orthopedics, featuring expert commentary from ICON's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
-
Engaging the crowds
A thought leadership piece by Peter Schueler which considers the importance of patient engagement and enrollment in Alzheimer's clinical trials.
This article is taken from International Clinical Trials November 2020, pages 10-12. © Samedan Ltd.
-
.jpg?w=545&itok=h3cy1Mkr "IPT discussed in technical publications.")
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2020, pages 38-40. © Samedan Ltd
-
The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
